tiprankstipranks
Trending News
More News >

YiChang HEC ChangJiang Pharmaceutical Announces EGM for Merger and Dividend Approval

Story Highlights
YiChang HEC ChangJiang Pharmaceutical Announces EGM for Merger and Dividend Approval

Don’t Miss TipRanks’ Half-Year Sale

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H ( (HK:1558) ) just unveiled an update.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has announced an extraordinary general meeting (EGM) to be held on July 21, 2025, to discuss and approve a merger agreement with Sunshine Lake Pharma Co., Ltd. The meeting will also consider the approval of a special dividend of HK$1.50 per share for shareholders, excluding the offeror and its subsidiaries. The merger and dividend decisions are significant for the company’s strategic direction and may impact shareholder value.

The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.

More about YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a pharmaceutical company based in the People’s Republic of China. It is involved in the development, manufacturing, and distribution of pharmaceutical products, focusing on the Chinese market.

Average Trading Volume: 9,690,048

Technical Sentiment Signal: Buy

Current Market Cap: HK$13.11B

For an in-depth examination of 1558 stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1